Loading
A phase 1/2 trial of ZG006 in small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06283719 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 265 participants planned, started 2024-09-02 and due to reach its primary completion in 2026-04. Interventions recorded: ZG006. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals, Small-cell lung cancer.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals, Small-cell lung cancer.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/